Mehabe score: 7 G Factor: 6 Piotski Score: 9 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 6 and Piotski score of 9.
Description
Jagsonpal Pharmaceuticals is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. The Company has operations in India and caters to both domestic and international markets.Site:JAGSNPHARMMain Symbol:JAGSNPHARM
Stock trades at 162.0, above its 50dma 156.06. It also trades above its 200dma 121.97. The stock remains bullish on techicals
The 52 week high is at 203.90 and the 52week low is at 37.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– is expected to give good quarter
– has delivered good profit growth of 39.32% CAGR over last 5 years
-Debtor days have improved from 39.79 to 24.59 days.
Weakness
– Stock is trading at 3.48 times its book value
-The company has delivered a poor sales growth of 5.55% over past five years.
– has a low return on equity of 9.88% for last 3 years.
Competition
– The industry trades at a mean P/E of 33.5x. Piramal Enterp. trades at the industry’s max P/E of 49.23x. JAGSNPHARM trades at a P/E of 19.8x
– Industry’s mean G-Factor is 2.5 while the mean Piotski score is 9.0. JAGSNPHARM has a G-Factor of 6 and Piotski scoreof 9.
– Average 1 month return for industry is -0.0%. The max 1- month return was given by Sun Pharma.Inds.: a return of 7.46 %
Quarterly Results
Sales for period ended Sep 2021 is Rs 59.49 cr compared to Rs 56.35 cr for period ended Sep 2020, a rise of 5.6%
Operating Profits reported at Rs 10.28 cr for period ended Sep 2021 vis-vis 4.84 for period ended Sep 2020 .
Operating Margins expanded 869.1 bps for period ended Sep 2021 vis-vis Sep 2020 .
The EPS for Sep 2021 was Rs 2.79 compared to Rs 2.61 for previous quarter ended Jun 2021 and Rs 1.53 for Sep 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 219.0 cr for period ended TTM vis-vis sales of Rs 188.0 cr for the period ended Mar 2021, a healthy growth of 14.2%. The 3 year sales cagr stood at 9.5%.
Operating margins expanded to 14.0% for period ended TTM vis-vis 10.0% for period ended Mar 2021, expansion of 400.0 bps.
Net Profit reported at Rs 25.0 cr for period ended TTM vis-vis sales of Rs 17.0 cr for the period ended Mar 2021, rising 32.0%.
Company recorded a healthy Net Profit CAGR of 52.9% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
CashFlow from operating activities: Rs 28.0 cr for period ended Mar 2021 vis-vis Rs 12.0 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 15.0% compared to 10.0% over the last 3 Years. – The stock has given a return of 296% on a 1 Year basis vis-vis a return of 80% over the last 3 Years. – The compounded sales growth on a TTM bassis is 49% vis-vis a compounded sales growth of 14% over the last 3 Years. – The compounded profit growth on a TTM basis is 155% vis-vis a compounded profit growth of 52% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has remained largely constant. The Jun 2021 public holding stood at 29.65% vis-vis 29.65% for Mar 2021
Conclusion
– is almost debt free.
– is expected to give good quarter
– has delivered good profit growth of 39.32% CAGR over last 5 years
-Debtor days have improved from 39.79 to 24.59 days. – Stock is trading at 3.48 times its book value
-The company has delivered a poor sales growth of 5.55% over past five years.
– has a low return on equity of 9.88% for last 3 years.
